Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma

NCT02371746 is registered in ClinicalTrials.gov with Envisia Therapeutics as lead sponsor.

NCT NCT02371746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02371746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma
Lead sponsor
Envisia Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2015
Completion date
February 13, 2019
Enrollment
41 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma and ocular hypertension